Evidence map›Paper›PMID 29225841›Full record

ArticleClinical case reports2017

Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis.

Massimiliano Bonifacio, Roberta Zanotti, Emanuele Guardalben, Elda Mimiola, Francesca Scognamiglio, Omar Perbellini, Giovanna De Matteis, Luis Escribano, Patrizia Bonadonna, Daniela Grigolato and 5 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Massimiliano BonifacioDepartment of Medicine Section of Hematology University of Verona Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.ORCID 0000-0003-0716-1686
Roberta ZanottiDepartment of Medicine Section of Hematology University of Verona Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.
Emanuele GuardalbenDepartment of Medicine Section of Hematology University of Verona Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.
Elda MimiolaDepartment of Medicine Section of Hematology University of Verona Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.
Francesca ScognamiglioDepartment of Hematology San Bortolo Hospital Vicenza Italy.
Omar PerbelliniDepartment of Hematology San Bortolo Hospital Vicenza Italy.
Giovanna De MatteisDepartment of Life and Reproduction Sciences Section of Clinical Biochemistry University of Verona Verona Italy.
Luis EscribanoServicio Central de Citometria (NUCLEUS) Centro de Investigacion del Cancer (IBMCC; CSIC/USAL) Salamanca Spain.
Patrizia BonadonnaMultidisciplinary Outpatients Clinic for Mastocytosis Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.
Daniela GrigolatoNuclear Medicine Unit Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.
Sergio BissoliNuclear Medicine Unit San Giacomo Apostolo Hospital Castelfranco Veneto Italy.
Alice ParisiDepartment of Diagnostics and Public Health Section of Pathological Anatomy University of Verona Verona Italy.
Alberto ZamòDepartment of Diagnostics and Public Health Section of Pathological Anatomy University of Verona Verona Italy.
Achille AmbrosettiDepartment of Medicine Section of Hematology University of Verona Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.
Maurizio RossiniMultidisciplinary Outpatients Clinic for Mastocytosis Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy.
University of Verona · ITAzienda Ospedaliera Universitaria Integrata Verona · ITOspedale San Bortolo · ITOspedale San Giacomo Apostolo · ITUniversidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with advanced variants of Systemic Mastocytosis may develop destructive bone lesions when massive mast cell (MC) infiltrates are present. Finding of large osteolyses in indolent systemic mastocytosis, typically characterized by low MC burden, should prompt investigations for an alternative explanation.

Indexed as

Non‐hodgkin lymphomaosteolysisprimary bone lymphomasystemic mastocytosistryptase

Identifiers

PMID29225841
PMCPMC5715414
OpenAlexW2767146682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.